GlassScriptPhysician profile
Heather Tran
NPI 1043734098
$11,323.39
in general payments reported to CMS, 2019-2025
31 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,198 · 2022: $4,593 · 2023: $1,575 · 2024: $1,960 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,433 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,432.70 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,256.67 | 2021-2025 | Winlevi |
| Abbvie INC. | $1,134.25 | 2021-2025 | |
| Genzyme Corporation | $1,051.92 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $983.51 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $614.82 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $611.82 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $505.98 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $484.80 | 2022-2025 | Otezla, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $330.03 | 2021-2025 | |
| Ucb, INC. | $319.62 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $279.49 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $273.26 | 2023-2024 | Vtama |
| Organon LLC | $140.10 | 2025 | Vtama |
| Lilly USA, LLC | $136.98 | 2021-2023 | Olumiant |
| Leo Pharma INC. | $134.47 | 2021-2025 | Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $123.55 | 2021-2022 | |
| Galderma Laboratories, L.P. | $121.22 | 2021-2025 | Nemluvio, Aklief |
| Biofrontera INC. | $113.48 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Hill Dermaceuticals, INC. | $89.45 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.58 | 2022-2025 | Cabtreo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Mayne Pharma Commercial LLC | $76.42 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $65.40 | 2021 | |
| Pfizer INC. | $62.70 | 2023-2024 | |
| Boston Scientific Corporation | $58.37 | 2025 | Wavewriter Alpha Prime 16 |
| Extremity Medical | $51.93 | 2021 | |
| Botanix Sb INC | $50.80 | 2025 | Sofdra |
| Novo Nordisk INC | $35.36 | 2025 | Ozempic, Rybelsus, Wegovy |
| Verrica Pharmaceuticals INC. | $21.78 | 2025 | Ycanth |
| Journey Medical Corporation | $14.38 | 2024 | |
| Epi Health, LLC | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.